Vedanta Biosciences Overview
- Year Founded
-
2010
- Status
-
Private
- Employees
-
137
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$3.9M
- Investors
-
37
Vedanta Biosciences General Information
Description
Developer of orally delivered defined bacterial consortia designed to treat inflammatory and infectious diseases. The company's platform includes libraries of bacteria derived from the human microbiome, vast datasets from human interventional studies, proprietary capabilities in consortium design, and end-to-end CGMP manufacturing through commercial launch, leading to the development of a potential new category of oral therapies based on defined consortia of bacteria isolated from the human microbiome and grown from pure clonal cell banks, enabling physicians to access oral therapies to treat autoimmune and inflammatory diseases efficiently.
Contact Information
Website
www.vedantabio.comCorporate Office
- 19 Blackstone Street
- Cambridge, MA 02139
- United States
Corporate Office
- 19 Blackstone Street
- Cambridge, MA 02139
- United States
Vedanta Biosciences Timeline
Vedanta Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 16. Grant | 30-Apr-2024 | $3.9M | Completed | Clinical Trials - Phase 3 | ||
| 15. Debt Refinancing | 21-Apr-2023 | Completed | Clinical Trials - Phase 3 | |||
| 14. Later Stage VC (Series D) | 05-Aug-2024 | Completed | Clinical Trials - Phase 3 | |||
| 13. Later Stage VC (Series D) | 19-Jul-2021 | Completed | Clinical Trials - Phase 3 | |||
| 12. Secondary Transaction - Private | 16-Apr-2021 | Completed | Clinical Trials - Phase 3 | |||
| 11. Later Stage VC | 31-Dec-2020 | Completed | Clinical Trials - Phase 3 | |||
| 10. Grant | 30-Sep-2020 | Completed | Clinical Trials - Phase 3 | |||
| 9. Debt - General | 16-Sep-2020 | Completed | Clinical Trials - Phase 3 | |||
| 8. Grant | 05-Dec-2019 | $5.8M | $123M | Completed | Clinical Trials - Phase 3 | |
| 7. Later Stage VC (Series C2) | 23-Sep-2019 | $25.6M | $123M | Completed | Clinical Trials - Phase 3 |
Vedanta Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C2 | ||||||||
| Series C | ||||||||
| Series B | 2,305,948 | $0.000100 | $22.65 | $22.65 | 1x | $22.65 | 15.79% | |
| Series A1 | 4,000,000 | $0.000100 | $1 | $1 | 1x | $1 | 27.39% |
Vedanta Biosciences Comparisons
Industry
Financing
Details
Vedanta Biosciences Competitors (28)
One of Vedanta Biosciences’s 28 competitors is Seres Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Seres Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Spyre Therapeutics | Corporation | Waltham, MA | ||||
| Morphic Therapeutic | Formerly VC-backed | Waltham, MA | ||||
| Abivax | Formerly PE-Backed | Paris, France | ||||
| AM-Pharma | Venture Capital-Backed | Utrecht, Netherlands |
Vedanta Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Vedanta Biosciences Patents
Vedanta Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4362961-A1 | Methods of colonizing a microbiome, treating and/or preventing inflammatory bowel disease and graft versus host disease | Pending | 28-Jun-2021 | ||
| US-20240173365-A1 | Methods of colonizing a microbiome, treating and/or preventing inflammatory bowel disease and graft versus host disease | Pending | 28-Jun-2021 | ||
| EP-4320221-A1 | Compositions and methods for treating cancer | Pending | 05-Apr-2021 | ||
| US-20240366691-A1 | Compositions and methods for treating cancer | Pending | 05-Apr-2021 | ||
| EP-4294413-A1 | Compositions and methods for suppressing pathogenic organisms | Pending | 18-Feb-2021 | A61K35/74 |
Vedanta Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Vedanta Biosciences Investors (37)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AMR Action Fund | Impact Investing | Minority | ||
| Atika Capital Management | Hedge Fund | Minority | ||
| Atlantic Neptune | Corporation | Minority | ||
| AXA Investment Managers | Asset Manager | Minority | ||
| Fiscus Ventures | Venture Capital | Minority |
Vedanta Biosciences FAQs
-
When was Vedanta Biosciences founded?
Vedanta Biosciences was founded in 2010.
-
Where is Vedanta Biosciences headquartered?
Vedanta Biosciences is headquartered in Cambridge, MA.
-
What is the size of Vedanta Biosciences?
Vedanta Biosciences has 137 total employees.
-
What industry is Vedanta Biosciences in?
Vedanta Biosciences’s primary industry is Drug Discovery.
-
Is Vedanta Biosciences a private or public company?
Vedanta Biosciences is a Private company.
-
What is Vedanta Biosciences’s current revenue?
The current revenue for Vedanta Biosciences is .
-
How much funding has Vedanta Biosciences raised over time?
Vedanta Biosciences has raised $366M.
-
Who are Vedanta Biosciences’s investors?
AMR Action Fund, Atika Capital Management, Atlantic Neptune, AXA Investment Managers, and Fiscus Ventures are 5 of 37 investors who have invested in Vedanta Biosciences.
-
Who are Vedanta Biosciences’s competitors?
Seres Therapeutics, Spyre Therapeutics, Morphic Therapeutic, Abivax, and AM-Pharma are some of the 28 competitors of Vedanta Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
